XOMA Royalty (XOMA) Income from Continuing Operations (2011 - 2026)
XOMA Royalty (XOMA) reported Income from Continuing Operations of 4465000.0 for Q1 2026, up 88.64% on a YoY basis from 2367000.0 in Q1 2025, and down 51.13% sequentially from 9137000.0 in Q4 2025.
XOMA Royalty (XOMA) Income from Continuing Operations (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of Income from Continuing Operations data on file, last reported at 4465000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 88.64% year-over-year to 4465000.0; the trailing twelve-month figure through Mar 2026 stood at 4857000.0 (up 109.43% YoY), and the FY2025 full-year result was 31712000.0, up 330.58% from the prior year.
- Income from Continuing Operations slipped to 4465000.0 in Q1 2026, from 9137000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9137000.0 in Q4 2025 to a low of 27059000.0 in Q2 2024.
- A 5-year average of 10313875.0 and a median of 11089500.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 830.49% in 2022 and surged 195.6% in 2025, its largest moves.
- Tracing XOMA's Income from Continuing Operations over 5 years: stood at 6261000.0 in 2022, then tumbled by 225.0% to 20348000.0 in 2023, then jumped by 53.03% to 9558000.0 in 2024, then surged by 195.6% to 9137000.0 in 2025, then plunged by 51.13% to 4465000.0 in 2026.
- Business Quant data shows XOMA's Income from Continuing Operations at 4465000.0 in Q1 2026, 9137000.0 in Q4 2025, and 11112000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | 9.14 Mn |
| Jun 30, 2025 | -11.11 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | -9.56 Mn |
| Sep 30, 2024 | -17.24 Mn |
| Jun 30, 2024 | -27.06 Mn |
| Mar 31, 2024 | -10.78 Mn |
| Dec 31, 2023 | -20.35 Mn |
| Sep 30, 2023 | -12.59 Mn |
| Jun 30, 2023 | -17.39 Mn |
| Mar 31, 2023 | -11.07 Mn |
| Dec 31, 2022 | -6.26 Mn |
| Sep 30, 2022 | -14.66 Mn |
| Jun 30, 2022 | -20.82 Mn |
| Mar 31, 2022 | -2.12 Mn |
| Dec 31, 2021 | 29.86 Mn |
| Sep 30, 2021 | -4.44 Mn |
| Jun 30, 2021 | -2.24 Mn |
| Mar 31, 2021 | -7.37 Mn |